Xuefu Zhuyu Decoction improves hyperlipidemia through the MAPK / NF ‐ κB and MAPK / PPARα / CPT ‐ 1A signaling pathway
The FASEB Journal · 2025
DOI: 10.1096/fj.202402688r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Jiajun Han und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Changchun University of Chinese Medicine, Jilin, China. Hauptthemen laut MEDLINE: Hyperlipidemias, Drugs, Chinese Herbal, PPAR alpha, NF-kappa B. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Jilin Provincial Scientific and Technological Development Program, Education Department of Jilin Province, Administration of Traditional Chinese Medicine of Jilin Province.
Abstract (Originalsprache)
Xuefu Zhuyu Decoction (XZD) is widely used in the treatment of cardiovascular diseases. The purpose of this study was to explore the pharmacological effects and molecular mechanisms of XZD in improving hyperlipidemia and to provide a theoretical framework for clinical application. In this study, the signaling pathways regulated by XZD in improving hyperlipidemia were predicted by network pharmacology. Molecular docking was used to verify the affinity between the components in XZD and the target. Furthermore, a hyperlipidemic model in rats was constructed through feeding a high‐fat diet. The effect of XZD on hyperlipidemia was verified by histopathological staining, Elisa, and western blot. The results found that the XZD improved dyslipidemia and inflammatory factor disorders, and inhibited liver function damage, pathological damage, and oxidative stress damage in hyperlipidemic rats. The findings from molecular docking and network pharmacology suggested that the mechanism of XZD improving hyperlipidemia may be closely related to the MAPK, NF‐κB, and PPAR pathways. This study demonstrated that the XZD inhibited liver lipid metabolism disorder and inflammatory response by regulating the MAPK/NF‐κB and MAPK/PPARα/CPT‐1A pathway, significantly improved liver histopathological damage and oxidative stress injury, and played a protective role in hyperlipidemic rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Changchun University of Chinese Medicine, Jilin, China.
- Department of Endocrinology and Metabolism, Jilin Province People's Hospital, Jilin, China.
- Research Center of Traditional Chinese Medicine, Affiliated Hospital to Changchun University of Chinese Medicine, Jilin, China.
ORCID-Profile: Jiajun Han, Yuyang Miao, Linze Song, Xianfeng Zhou, Yan Liu, Lin Wang, Kai Zhu, He Ma, Yan Ma, Qingjie Li, Dong Han
Förderung
- Jilin Provincial Scientific and Technological Development Program
- Education Department of Jilin Province
- Administration of Traditional Chinese Medicine of Jilin Province
- Health Commission of Jilin Province
Zitieren
APA
Han, J., Miao, Y., Song, L., Zhou, X., Liu, Y., Wang, L., Zhu, K., Ma, H., Ma, Y., Li, Q., & Han, D. (2025). Xuefu Zhuyu Decoction improves hyperlipidemia through the MAPK / NF ‐ κB and MAPK / PPARα / CPT ‐ 1A signaling pathway. The FASEB Journal. https://doi.org/10.1096/fj.202402688r
Vancouver
Han J, Miao Y, Song L, Zhou X, Liu Y, Wang L, et al. Xuefu Zhuyu Decoction improves hyperlipidemia through the MAPK / NF ‐ κB and MAPK / PPARα / CPT ‐ 1A signaling pathway. The FASEB Journal. 2025. doi:10.1096/fj.202402688r
BibTeX
@article{Han2025,
author = {Han, Jiajun and Miao, Yuyang and Song, Linze and Zhou, Xianfeng and Liu, Yan and Wang, Lin and Zhu, Kai and Ma, He and Ma, Yan and Li, Qingjie and Han, Dong},
title = {Xuefu Zhuyu Decoction improves hyperlipidemia through the MAPK / NF ‐ κB and MAPK / PPARα / CPT ‐ 1A signaling pathway},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202402688r}
}
EUVIMED